Lucia Mazzacurati

Modulation of the sensitivity to ruxolitinib-mediated JAK2 inhibition by mutationally activated SHP2 exhibits cell context dependency in pre-clinical models of myeloproliferative neoplasms

This study shows that an activating SHP2 mutation in MPN cell models alters sensitivity to JAK2 inhibition, with context-dependent effects observed in different cell lines.

Controlling treatment toxicity in ovarian cancer to prime the patient for tumor extinction therapy

This paper develops computational frameworks to design personalized multi-strike therapies for ovarian cancer that reduce toxicity while enhancing tumor extinction.